We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Our knowledge, expertise & publications
Deals & Cases
26 October 2022
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. VISCHER acted as legal advisor to Anokion in this transaction. The team included Matthias Staehelin, Vincent Reardon and Luzius Zumstein (all Corporate/M&A).
Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
VISCHER advised Mosanna Therapeutics AG in closing an extension of the Seed Financing Round with...
Intel Capital, a leading investor in the future of compute, has invested in UNISERS AG, a Swiss...
Bachem Holding AG (SIX:BANB) has raised a total of CHF 108.1 million through an accelerated...
Opt-in for our regular updates, news, views, insights and more.